Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV8SUM)

• Drug Name: desmosterol Drug Info
• Synonyms: DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 439577
  ChEBI ID: CHEBI:17737
  CAS Number: CAS 313-04-2
  TTD Drug ID: DMV8SUM
  INTEDE Drug ID: DR0437

Molecule-Related Drug Atlas

Drug(s) Targeting Oxysterols receptor LXR-beta (NR1H2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VTB-38543	DMNY3J0	Atopic dermatitis	EA80	Phase 2	[9]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[10]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[11]
WAY-214950	DM8ODI7	Discovery agent	N.A.	Investigative	[12]
27-hydroxycholesterol	DM2L6OZ	Discovery agent	N.A.	Investigative	[13]
22R-hydroxycholesterol	DME8273	Discovery agent	N.A.	Investigative	[14]
GSK-9772	DM4WS3R	Discovery agent	N.A.	Investigative	[15]
Riccardin C	DM6MYGX	Discovery agent	N.A.	Investigative	[16]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	DMH76SO	Discovery agent	N.A.	Investigative	[17]
AZ12260493	DMQ5H2V	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[19]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[20]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[21]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[22]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[23]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[24]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[25]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[26]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[27]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[28]

Drug(s) Targeting Oxysterols receptor LXR-alpha (NR1H3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9073931, E2	DMK9FJG	N. A.	N. A.	Patented	[29]
BDBM50177019	DMEL28G	N. A.	N. A.	Patented	[30]
US9006244, E2b	DMP0TBO	N. A.	N. A.	Patented	[31]
US9073931, E1	DM2Z43I	N. A.	N. A.	Patented	[29]
US9006244, E1	DMBF1C0	N. A.	N. A.	Patented	[31]
BDBM50177012	DM52IQF	N. A.	N. A.	Patented	[30]
US9006244, E2a	DMPDF9B	N. A.	N. A.	Patented	[31]
67S	DMJL1MB	N. A.	N. A.	Patented	[30]
US9073931, E3	DMCYM8P	N. A.	N. A.	Patented	[29]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[11]

Drug(s) Affected By E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[32]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[7]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Betaine	DMGRZW2	Cystitis	GC00	Approved	[7]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[34]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[35]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[36]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[37]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[32]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[7]

Drug(s) Affected By C-type lectin domain family 4 member E (CLEC4E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[39]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[40]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[41]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[42]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[6]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[43]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[44]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[45]

Drug(s) Affected By Sterol 26-hydroxylase, mitochondrial (CYP27A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[46]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[47]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[48]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[49]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[50]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[51]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[52]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[54]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[55]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[2]
Oxysterols receptor LXR-alpha (NR1H3)	TTECBXN	NR1H3_HUMAN	Agonist	[3]
Oxysterols receptor LXR-beta (NR1H2)	TTXA6PH	NR1H2_HUMAN	Agonist	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Delta(24)-sterol reductase (DHCR24)	DEAXY04	DHC24_HUMAN	Substrate	[4]
Sterol Delta(7)-reductase (DHCR7)	DEL7GFA	DHCR7_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-type lectin domain family 4 member E (CLEC4E)	OT7P8ICY	CLC4E_HUMAN	Gene/Protein Processing	[6]
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)	OTBTA03N	MARH6_HUMAN	Protein Interaction/Cellular Processes	[7]
Sterol 26-hydroxylase, mitochondrial (CYP27A1)	OT649C01	CP27A_HUMAN	Regulation of Drug Effects	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2748).
• [2] Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72.
• [3] Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
• [4] Alzheimer's disease: brain desmosterol levels. J Alzheimers Dis. 2013;33(3):881-8.
• [5] Inhibitors of 7-dehydrocholesterol reductase: screening of a collection of pharmacologically active compounds in Neuro2a cells. Chem Res Toxicol. 2016 May 16;29(5):892-900.
• [6] Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses. J Biol Chem. 2015 Oct 16;290(42):25322-32. doi: 10.1074/jbc.M115.645234. Epub 2015 Aug 20.
• [7] Cholesterol increases protein levels of the E3 ligase MARCH6 and thereby stimulates protein degradation. J Biol Chem. 2019 Feb 15;294(7):2436-2448. doi: 10.1074/jbc.RA118.005069. Epub 2018 Dec 13.
• [8] Novel sterols synthesized via the CYP27A1 metabolic pathway. Arch Biochem Biophys. 2003 Dec 1;420(1):35-9. doi: 10.1016/j.abb.2003.09.028.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
• [12] Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
• [13] 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
• [14] An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
• [15] Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
• [16] Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
• [17] Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 601).
• [19] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [20] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [21] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [22] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [23] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [24] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [25] Clinical pipeline report, company report or official report of ENYO Pharma.
• [26] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [27] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [28] Clinical pipeline report, company report or official report of Metacrine.
• [29] Liver X receptor modulators. US9073931.
• [30] Piperazine derivatives as liver X receptor modulators. US10144715.
• [31] Liver X receptor modulators. US9006244.
• [32] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [33] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [34] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [35] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [36] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [37] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [38] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [39] A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res. 2012 Jul;130(1):45-51. doi: 10.1016/j.thromres.2011.12.009. Epub 2012 Jan 2.
• [40] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [41] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [42] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [43] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [44] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [45] Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
• [46] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [47] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [48] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [49] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [50] PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res. 2007 Feb;48(2):373-84.
• [51] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [52] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [53] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [54] Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
• [55] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.